ROS, especially H2O2, reduce SLC7A11 and GPX4 expression in cervical cancer and prostate cancer (Liu S. et al., 2024; Alakkal et al., 2022); additionally, ROS stimulate BTB domain and CNC homolog 1 (BACH1) degradation by decreasing the expression of ubiquitin carboxyl-terminal hydrolase 47 (USP47), which can deubiquitinate BACH1. Here, GPX4 is linked to prostate carcinoma.